Monoclonal Antibody-Directed Therapy
The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading group...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_78804 | ||
005 | 20220224 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220224s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-2872-4 | ||
020 | |a 9783036528724 | ||
020 | |a 9783036528731 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-2872-4 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
072 | 7 | |a KNDP |2 bicssc | |
100 | 1 | |a Kayser, Veysel |4 edt | |
700 | 1 | |a Datta-Mannan, Amita |4 edt | |
700 | 1 | |a Kayser, Veysel |4 oth | |
700 | 1 | |a Datta-Mannan, Amita |4 oth | |
245 | 1 | 0 | |a Monoclonal Antibody-Directed Therapy |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (142 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
650 | 7 | |a Pharmaceutical industries |2 bicssc | |
653 | |a therapeutic antibody | ||
653 | |a stability | ||
653 | |a aggregation | ||
653 | |a manufacture challenges | ||
653 | |a formulation | ||
653 | |a antibodies | ||
653 | |a site-specific conjugation | ||
653 | |a bioconjugates | ||
653 | |a ADC | ||
653 | |a antibody-drug conjugates | ||
653 | |a payloads | ||
653 | |a linkers | ||
653 | |a nucleic acids | ||
653 | |a ADME | ||
653 | |a developability | ||
653 | |a glycosylation | ||
653 | |a post-translational modifications | ||
653 | |a pharmacokinetics | ||
653 | |a effector functions | ||
653 | |a antibody-dependent cell-mediated cytotoxicity | ||
653 | |a complement-dependent cytotoxicity | ||
653 | |a immunogenicity | ||
653 | |a pharmacodynamics | ||
653 | |a glycoengineering | ||
653 | |a type III secretion system | ||
653 | |a prophylaxis | ||
653 | |a antibacterials | ||
653 | |a antibiotics | ||
653 | |a HIV/AIDS | ||
653 | |a co-formulation | ||
653 | |a high concentration | ||
653 | |a analytical characterization | ||
653 | |a antibody (s) | ||
653 | |a T-cell engagers | ||
653 | |a bispecific antibodies | ||
653 | |a immunotherapy | ||
653 | |a oncology | ||
653 | |a antibody engineering | ||
653 | |a immunological synapse | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4899 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78804 |7 0 |z DOAB: description of the publication |